Special Issue

Inflammatory Bowel Disease (IBD): Diagnosis and Personalized Treatment

Message from the Guest Editor

The *Journal of Personalized Medicine* invites submissions to this Special Issue, which focuses on the latest advancements in the diagnosis and personalized treatment of IBD. This Special Issue aims to explore innovative diagnostic tools, biomarkers, and therapeutic strategies tailored to individual patient profiles, enhancing the precision and efficacy of IBD management. We welcome the submission of original research articles, reviews, and clinical studies that address the molecular mechanisms, genetic predispositions, and environmental factors influencing IBD. Topics of interest for this Special Issue include, but are not limited to, the following:

- Novel diagnostic biomarkers and imaging techniques;
- Genetic and epigenetic profiling in IBD;
- Personalized pharmacotherapy and biologics;
- Microbiome-based interventions;
- Multi-Omics approaches;
- Artificial intelligence;
- Patient-reported outcomes and quality of life in personalized treatment.

This Special Issue seeks to provide a comprehensive overview of the current state and future directions in personalized medicine for IBD, fostering a deeper understanding and improved clinical outcomes for patients worldwide.

Guest Editor

Dr. Abigail Raffner (formerly Basson)

1. Department of Nutrition, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
2. Division of Gastroenterology & Liver Diseases, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
3. Digestive Health Research Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA

Deadline for manuscript submissions

25 December 2025

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).